10/28/2020  9:02:42 PM Chg. -3.24 Volume Bid9:07:01 PM Ask9:07:01 PM Market Capitalization Dividend Y. P/E Ratio
73.26USD -4.24% 3.18 mill.
Turnover: 185.66 mill.
73.01Bid Size: 400 75.84Ask Size: 400 46.33 bill.USD 0.00% 44.32

Business description

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.
 

Management board & Supervisory board

CEO
Michael A. Mussallem
Management board
Scott B. Ullem, Arnold A. Pinkston, Bernard J. Zovighian, Christine Z. McCauley, Daveen Chopra, Dirksen J. Lehman, Donald E. Bobo, Jr., Gary I. Sorsher, Humin Wang, Jean-Luc Lemercier, Joseph Nuzzolese, Katie Szyman, Larry L. Wood, Todd J. Brinton
Supervisory board
Michael A. Mussallem, Dr. William J. Link, Kieran T. Gallahue, Leslie S. Heisz, Martha H. Marsh, Nicholas J. Valeriani, Paul A. LaViolette, Ramona Sequeira, Steven R. Loranger
 

Company data

Name: Edwards Lifesciences Corp.
Address: One Edwards Way,Irvine, California 92614, USA
Phone: +1-949-250-2500
Fax: -
E-mail: -
Internet: www.edwards.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 83.52%
IPO date: -

Investor relations

Name: David K. Erickson
IR phone: +1-949-250-2806
IR Fax: +1-949-756-4515
IR e-mail: investor_relations@edwards.com

Main Shareholders

Freefloat
 
83.52%
BlackRock, Inc.
 
8.70%
The Vanguard Group, Inc.
 
7.78%